182 related articles for article (PubMed ID: 32488251)
1. Are apixaban and rivaroxaban distributed into human breast milk to clinically relevant concentrations?
Zhao Y; Arya R; Couchman L; Patel JP
Blood; 2020 Oct; 136(15):1783-1785. PubMed ID: 32488251
[No Abstract] [Full Text] [Related]
2. Comparison of apixaban to rivaroxaban and enoxaparin in acute cancer-associated venous thromboembolism.
Wysokinski WE; Houghton DE; Casanegra AI; Vlazny DT; Bott-Kitslaar DM; Froehling DA; Hodge DO; Peterson LG; Mcbane RD
Am J Hematol; 2019 Nov; 94(11):1185-1192. PubMed ID: 31378995
[TBL] [Abstract][Full Text] [Related]
3. [Not Available].
Själander S; Själander A
Lakartidningen; 2018 Dec; 115():. PubMed ID: 30512136
[No Abstract] [Full Text] [Related]
4. Non-activated prothrombin complex concentrates for major bleeding in patients on apixaban and rivaroxaban.
Sheikh-Taha M
Intern Emerg Med; 2020 Sep; 15(6):1123-1124. PubMed ID: 31664661
[No Abstract] [Full Text] [Related]
5. Safety and effectiveness of rivaroxaban and apixaban in patients with venous thromboembolism: a nationwide study.
Sindet-Pedersen C; Staerk L; Pallisgaard JL; Gerds TA; Berger JS; Torp-Pedersen C; Gislason GH; Olesen JB
Eur Heart J Cardiovasc Pharmacother; 2018 Oct; 4(4):220-227. PubMed ID: 29945162
[TBL] [Abstract][Full Text] [Related]
6. Using a low-molecular weight heparin-calibrated anti-factor Xa assay to assess the concentration of apixaban and rivaroxaban.
von Horn H; Rasmusson A; Söderblom L; Malmström RE; Antovic J
Int J Lab Hematol; 2022 Feb; 44(1):163-167. PubMed ID: 34523813
[TBL] [Abstract][Full Text] [Related]
7. Dissociation between the pharmacokinetics and pharmacodynamics of once-daily rivaroxaban and twice-daily apixaban: a randomized crossover study.
Kreutz R; Persson PB; Kubitza D; Thelen K; Heitmeier S; Schwers S; Becka M; Hemmrich M
J Thromb Haemost; 2017 Oct; 15(10):2017-2028. PubMed ID: 28805299
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of direct oral factor Xa inhibitors compared with warfarin in patients with morbid obesity: a single-centre, retrospective analysis of chart data.
Kushnir M; Choi Y; Eisenberg R; Rao D; Tolu S; Gao J; Mowrey W; Billett HH
Lancet Haematol; 2019 Jul; 6(7):e359-e365. PubMed ID: 31133411
[TBL] [Abstract][Full Text] [Related]
9. Physiologically-Based Pharmacokinetic Modeling for the Prediction of a Drug-Drug Interaction of Combined Effects on P-glycoprotein and Cytochrome P450 3A.
Otsuka Y; Choules MP; Bonate PL; Komatsu K
CPT Pharmacometrics Syst Pharmacol; 2020 Nov; 9(11):659-669. PubMed ID: 33030266
[TBL] [Abstract][Full Text] [Related]
10. Effectiveness and safety of apixaban and rivaroxaban for acute venous thromboembolism therapy in patients with extremes in bodyweight.
Wysokinski WE; Froehling DA; Houghton DE; McBane RD; Vlazny DT; Bott-Kitslaar DM; Kuczmik W; Sutkowska K; Bator K; Hodge DO; Peterson LG; Casanegra AI
Eur J Haematol; 2020 Oct; 105(4):484-494. PubMed ID: 32557773
[TBL] [Abstract][Full Text] [Related]
11. Monitoring the roles of prothrombin activation fragment 1 and 2 (F1 + 2) in patients with atrial fibrillation receiving rivaroxaban and apixaban.
Ueno EI; Fujibayashi K; Sawaguchi J; Yasuda Y; Takano S; Fujioka N; Kawai Y; Fujita H; Tanaka Y; Kajinami K
J Thromb Thrombolysis; 2020 Aug; 50(2):371-379. PubMed ID: 32166540
[TBL] [Abstract][Full Text] [Related]
12. [Peri-Interventional Management of Direct Oral Anticoagulants - Balancing Benefits and Risks].
Dülgeroglu J; Schmidt D
Praxis (Bern 1994); 2018 Apr; 107(9-10):485-493. PubMed ID: 29690851
[No Abstract] [Full Text] [Related]
13. Comparison of Anti-Xa Activity in Patients Receiving Apixaban or Rivaroxaban.
Bookstaver DA; Sparks K; Pybus BS; Davis DK; Marcsisin SR; Sousa JC
Ann Pharmacother; 2018 Mar; 52(3):251-256. PubMed ID: 29047306
[TBL] [Abstract][Full Text] [Related]
14. Rivaroxaban and Apixaban for Initial Treatment of Acute Venous Thromboembolism of Atypical Location.
Janczak DT; Mimier MK; McBane RD; Kamath PS; Simmons BS; Bott-Kitslaar DM; Lenz CJ; Vargas ER; Hodge DO; Wysokinski WE
Mayo Clin Proc; 2018 Jan; 93(1):40-47. PubMed ID: 29217335
[TBL] [Abstract][Full Text] [Related]
15. Safety of apixaban and rivaroxaban in patients with atrial fibrillation on hemodialysis.
Ito H
Eur J Intern Med; 2024 Jun; 124():154-155. PubMed ID: 38342714
[No Abstract] [Full Text] [Related]
16. Efficacy and safety of Xa inhibitors for the treatment of cancer-associated venous thromboembolism.
Kimpton M; Carrier M
Expert Opin Drug Saf; 2019 Apr; 18(4):313-320. PubMed ID: 30925842
[TBL] [Abstract][Full Text] [Related]
17. Factor Xa inhibitors in clinical practice: Comparison of pharmacokinetic profiles.
Goto E; Horinaka S; Ishimitsu T; Kato T
Drug Metab Pharmacokinet; 2020 Feb; 35(1):151-159. PubMed ID: 32007354
[TBL] [Abstract][Full Text] [Related]
18. Direct factor Xa inhibitors (rivaroxaban and apixaban) versus enoxaparin for the prevention of venous thromboembolism after total knee replacement: A meta-analysis of 6 randomized clinical trials.
Ma G; Zhang R; Wu X; Wang D; Ying K
Thromb Res; 2015 May; 135(5):816-22. PubMed ID: 25728496
[TBL] [Abstract][Full Text] [Related]
19. Modern Treatment Modalities and Duration of Treatment for Venous Thromboembolism.
Robert-Ebadi H; Righini M
Ther Umsch; 2016; 73(10):618-625. PubMed ID: 28045360
[No Abstract] [Full Text] [Related]
20. DOAC plasma levels measured by chromogenic anti-Xa assays and HPLC-UV in apixaban- and rivaroxaban-treated patients from the START-Register.
Cini M; Legnani C; Padrini R; Cosmi B; Dellanoce C; De Rosa G; Marcucci R; Pengo V; Poli D; Testa S; Palareti G
Int J Lab Hematol; 2020 Apr; 42(2):214-222. PubMed ID: 32039550
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
